Abstract
The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn’s disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.
Keywords: Crohn’s disease, immunosuppression, inflammatory bowel disease, janus kinase, tofacitinib, ulcerative colitis.
Current Drug Targets
Title:Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Volume: 14 Issue: 12
Author(s): Lucine Vuitton, Stéphane Koch and Laurent Peyrin-Biroulet
Affiliation:
Keywords: Crohn’s disease, immunosuppression, inflammatory bowel disease, janus kinase, tofacitinib, ulcerative colitis.
Abstract: The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn’s disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.
Export Options
About this article
Cite this article as:
Vuitton Lucine, Koch Stéphane and Peyrin-Biroulet Laurent, Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990160
DOI https://dx.doi.org/10.2174/13894501113149990160 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures
Current Pharmaceutical Design 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry SYNTHESIS AND APPLICATIONS OF Fe3O4/SiO2 CORE-SHELL MATERIALS
Current Pharmaceutical Design Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Molecular Docking, 3D-QSAR, Fingerprint-Based 2D-QSAR, Analysis of Pyrimidine, and Analogs of ALK (Anaplastic Lymphoma Kinase) Inhibitors as an Anticancer Agent
Letters in Drug Design & Discovery Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets